MiMedx Group Q1 EPS Forecast Reduced by Northland Securities

MiMedx Group, Inc (NASDAQ:MDXG) – Stock analysts at Northland Securities dropped their Q1 2026 earnings per share (EPS) estimates for shares of MiMedx Group in a research note issued on Friday, April 17th. Northland Securities analyst C. Byrnes now expects that the company will post earnings per share of ($0.07) for the quarter, down from their previous forecast of ($0.03). The consensus estimate for MiMedx Group’s current full-year earnings is $0.12 per share. Northland Securities also issued estimates for MiMedx Group’s Q2 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.09) EPS and FY2027 earnings at $0.06 EPS.

MDXG has been the topic of a number of other research reports. Cantor Fitzgerald lowered their target price on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $7.00 target price (down from $10.00) on shares of MiMedx Group in a research report on Monday. Wall Street Zen downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. UBS Group set a $10.00 target price on MiMedx Group in a research report on Monday, February 23rd. Finally, Citigroup began coverage on MiMedx Group in a research report on Monday, February 23rd. They issued a “market outperform” rating on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

MiMedx Group Price Performance

NASDAQ:MDXG opened at $3.20 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.92 and a current ratio of 4.32. The stock’s 50-day simple moving average is $4.38 and its 200 day simple moving average is $5.79. The company has a market cap of $475.42 million, a P/E ratio of 10.00 and a beta of 1.65. MiMedx Group has a 52-week low of $3.18 and a 52-week high of $7.99.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $118.10 million for the quarter, compared to the consensus estimate of $106.78 million. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.

Hedge Funds Weigh In On MiMedx Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. Kemnay Advisory Services Inc. bought a new position in MiMedx Group during the fourth quarter worth about $48,000. State of Alaska Department of Revenue bought a new position in MiMedx Group during the third quarter worth about $54,000. Jain Global LLC bought a new position in MiMedx Group during the fourth quarter worth about $73,000. Wealth Enhancement Advisory Services LLC bought a new position in MiMedx Group during the third quarter worth about $84,000. Finally, Virtu Financial LLC bought a new position in MiMedx Group during the fourth quarter worth about $78,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.